XML 36 R22.htm IDEA: XBRL DOCUMENT v3.3.1.900
Selected Quarterly Financial Data (Unaudited)
 12 Months Ended
Oct. 31, 2015
Quarterly Financial Information Disclosure [Abstract]  
Selected Quarterly Financial Data (Unaudited)
Selected Quarterly Financial Data (Unaudited)

(In millions, except per share amounts)
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter*
2015
 
 
 
 
 
 
 
Net sales
$
445.2

 
$
434.7

 
$
461.7

 
$
455.5

Gross profit
$
276.4

 
$
267.7

 
$
272.9

 
$
253.3

Income before income taxes
$
67.5

 
$
67.0

 
$
44.6

 
$
36.4

Net income attributable to Cooper stockholders
$
61.2

 
$
60.7

 
$
45.0

 
$
36.7

Earnings per share attributable to Cooper stockholders - basic
$
1.27

 
$
1.25

 
$
0.92

 
$
0.76

Earnings per share attributable to Cooper stockholders - diluted
$
1.25

 
$
1.23

 
$
0.91

 
$
0.75

2014
 
 
 
 
 
 
 
Net sales
$
405.0

 
$
412.3

 
$
432.5

 
$
468.0

Gross profit
$
262.9

 
$
268.5

 
$
280.6

 
$
279.6

Income before income taxes
$
79.5

 
$
87.8

 
$
94.4

 
$
34.9

Net income attributable to Cooper stockholders
$
71.8

 
$
79.2

 
$
88.1

 
$
30.8

Earnings per share attributable to Cooper stockholders - basic
$
1.50

 
$
1.65

 
$
1.83

 
$
0.64

Earnings per share attributable to Cooper stockholders - diluted
$
1.47

 
$
1.62

 
$
1.80

 
$
0.63



*Fiscal fourth quarter 2015 results include charges for integration and restructuring activities related to recent acquisitions. Fiscal fourth quarter 2014 results include the operating results of Sauflon Pharmaceuticals Ltd., acquired in August 2014, and the related acquisition, integration and restructuring costs. Please refer to Management's Discussion and Analysis of Financial Condition and Results of Operations in Item 7 and Note 2 and Note 3 for additional information.